Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Manufacturing and API Supply as Strategic Barriers The sheer complexity of manufacturing GLP-1 and GIP peptides at a global scale serves as a practical, non-legal barrier to competition
Whether its evaluating coverage strategies or helping members understand all their options, this guide outlines critical insights into the GLP-1 market and actionable next steps for benefits managers
75% of the lawsuits listed gastroparesis/stomach paralysis in the complaint, 18% listed ileus, 8% listed gallbladder complications, and 8% listed other severe gastrointestinal conditions
B., Fitch, A., Gigliotti, L., & Mozaffarian, D
de et al
Akkermansia muciniphila, a mucin-degrading bacterium residing in the mucus layer of the gut, has garnered significant attention for its potential role in metabolic regulation
US$ 22.29
US$ 28.62
US$ 26.64
